Replimune Group, Inc. (NASDAQ:REPL) Receives $19.14 Consensus PT from Analysts

Shares of Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) have received a consensus recommendation of "Buy" from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $19.14.

Several equities research analysts have commented on the stock. BMO Capital Markets boosted their price target on shares of Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday. HC Wainwright boosted their price target on shares of Replimune Group from $17.00 to $21.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, Jefferies Financial Group boosted their price target on shares of Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, December 4th.

Replimune Group Stock Down 1.2 %

REPL traded down $0.16 during trading on Friday, hitting $13.59. The company had a trading volume of 727,841 shares, compared to its average volume of 695,994. Replimune Group has a one year low of $4.92 and a one year high of $17.00. The firm's 50-day moving average price is $12.28 and its 200 day moving average price is $11.35. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07. As a group, equities research analysts predict that Replimune Group will post -2.88 EPS for the current fiscal year.

Insider Activity at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the business's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the sale, the chief executive officer now owns 202,014 shares of the company's stock, valued at $2,509,013.88. The trade was a 4.72 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the business's stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the sale, the insider now directly owns 109,885 shares of the company's stock, valued at $1,184,560.30. This represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. 8.80% of the stock is owned by company insiders.

Institutional Trading of Replimune Group

Institutional investors and hedge funds have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its holdings in shares of Replimune Group by 12.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company's stock valued at $5,313,000 after acquiring an additional 52,498 shares in the last quarter. Geode Capital Management LLC grew its position in Replimune Group by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company's stock worth $15,657,000 after acquiring an additional 217,308 shares during the last quarter. Barclays PLC grew its position in Replimune Group by 165.5% during the 3rd quarter. Barclays PLC now owns 158,491 shares of the company's stock worth $1,738,000 after acquiring an additional 98,791 shares during the last quarter. LMR Partners LLP grew its position in Replimune Group by 145.8% during the 3rd quarter. LMR Partners LLP now owns 82,479 shares of the company's stock worth $904,000 after acquiring an additional 48,920 shares during the last quarter. Finally, Millennium Management LLC grew its position in Replimune Group by 575.1% during the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company's stock worth $28,062,000 after acquiring an additional 2,656,173 shares during the last quarter. Institutional investors own 92.53% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.